Linc

Linc Net Debt / EBITDA

The Net Debt to EBITDA of Linc (LINC.ST) as of Nov 10, 2026 is -0.79. In the previous year, Net Debt to EBITDA was 0.67 — a change of -218.95% (lower).

Net Debt / EBITDA

-0.79

YoY

-218.95%

Last updated:

Net Debt to EBITDA of Linc is 2023 -0.79 . Net Debt to EBITDA of Linc was 2022 0.67 . It decreases by -218.95% lower compared to the previous year.

The Linc Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-0.12 SEK
Jan 1, 2019
-0.06 SEK
Jan 1, 2020
-0.02 SEK
Jan 1, 2021
17.70 SEK
Jan 1, 2022
0.67 SEK
Jan 1, 2023
-0.79 SEK
The Linc Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-0.79-218.95%
0.67-96.22%
17.70-79,388.42%
-0.02-63.16%
-0.06-47.61%
-0.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Net Debt to EBITDA of Linc is -0.79 in 2023.

Net Debt to EBITDA of Linc changed from 0.67 to -0.79, representing a -218.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Linc since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Linc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Linc

All Key Metrics — Linc